Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Feb;126(1):221-6.
doi: 10.1007/s10549-010-1235-y. Epub 2010 Nov 3.

Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial

Kelly-Anne Phillips  1 , Julie Aldridge, Karin Ribi, Zhuoxin Sun, Alastair Thompson, Vernon Harvey, Beat Thürlimann, Fatima Cardoso, Olivia Pagani, Alan S Coates, Aron Goldhirsch, Karen N Price, Richard D Gelber, Jürg Bernhard
Affiliations
Randomized Controlled Trial

Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial

Kelly-Anne Phillips et al. Breast Cancer Res Treat. 2011 Feb.

Abstract

Endocrine therapy for breast cancer may affect cognition. The purpose of this study was to examine whether cognitive function improves after cessation of adjuvant endocrine therapy. Change in cognitive function was assessed in 100 postmenopausal breast cancer patients in the BIG 1-98 trial, who were randomized to receive 5 years of adjuvant tamoxifen or letrozole alone or in sequence. Cognitive function was evaluated by computerized tests during the fifth year of trial treatment (Y5) and 1 year after treatment completion (Y6). Cognitive test scores were standardized according to age-specific norms and the change assessed using the Wilcoxon signed-rank test. There was significant improvement in the composite cognitive function score from Y5 to Y6 (median of change = 0.22, effect size = 0.53, P < 0.0001). This improvement was consistent in women taking either tamoxifen or letrozole at Y5 (P = 0.0006 and P = 0.0002, respectively). For postmenopausal patients who received either adjuvant letrozole or tamoxifen alone or in sequence, cognitive function improved after cessation of treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest Financial disclosures: The substudy was funded by Novartis. Novartis contracted with the International Breast Cancer Study Group (IBCSG) for provision of services related to the conduct and management of the trial. Dr. Thürlimann owns stock in Novartis; Dr. Cardoso has received consulting and/or lecture fees from Novartis, Dr. Thompson and Dr. Goldhirsch have received honoraria from Novartis. The remaining authors have no conflicts to report.

Figures

Fig. 1
Fig. 1
CONSORT diagram of the BIG 1-98 Cognitive Function Substudy. T tamoxifen for 5 years, L letrozole for 5 years, T → L tamoxifen for 2 years followed by letrozole for three years, L → T letrozole for 2 years followed by tamoxifen for 3 years, ET endocrine therapy, Y5 cognitive function assessment taken at the end of 5 years of ET, Y6 cognitive function assessment taken approximately 1 year after completion of ET
Fig. 2
Fig. 2
Change in median age-adjusted composite score from the assessment taken at the end of endocrine therapy (Y5) to the assessment taken approximately 1 year after completion of endocrine therapy (Y6) according to endocrine therapy received, showing significant improvement in cognition, as measured by the composite score, from Y5 to Y6
See this image and copyright information in PMC

References

    1. McCarty KS, Jr, Silva JS, Cox EB, et al. Relationship of age and menopausal status to estrogen receptor content in primary carcinoma of the breast. Ann Surg. 1983;197:123–127. - PMC - PubMed
    1. Schilder CM, Seynaeve C, Beex WB, et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol. 2010;28:1294–1300. - PubMed
    1. Collins B, Mackenzie J, Stewart A, et al. Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. Psychooncology. 2009;18:811–821. - PubMed
    1. Bender CM, Sereika SM, Berga SL, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology. 2006;15:422–430. - PubMed
    1. Jenkins V, Shilling V, Fallowfield L, et al. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? a pilot study. Psychooncology. 2004;13:61–66. - PubMed

Publication types